Board of directors

Leonard Kruimer

Member of the board of directors

Nationality: Dutch | Year of Birth: 1958

Leonard Kruimer has been a member of the board since 2022. He is also chairman of the audit committee. He is independent in accordance with the Swiss Code of Best Practice for Corporate Governance.

Mr. Kruimer has more than 30 years of experience in corporate finance, planning, and strategy, including
20 years in senior executive positions in private and publicly listed biotechnology companies. He was member of the investment advisory council of Karmijn Kapitaal from 2013 to 2023 and director of the board of Oncolytics Inc. from 2019 to 2022. Mr. Kruimer served as CFO of SkylineDx BV from 2015 to 2016, of
BBB Therapeutics from 2014 to 2015, and of Crucell N.V. from 1997 to 2011. Prior to Crucell, he held various other senior executive roles. He was also a consultant with McKinsey & Co. and an auditor at Price Waterhouse & Company, New York.

Mr. Kruimer is chairman of the board of of BioInvent International AB, member of the board of Pharming Group NV, member of the board of Zealand Pharma A/S, and director of AI Global Investments (Netherlands)
PCC Ltd.

Mr. Kruimer holds a master of business administration from Harvard Business School, a bachelor degree in accounting and finance from the University of Massachusetts Amherst, and is a certified public accountant in the State of New York.